Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.04 per share when it actually produced a loss of $0.06, delivering a surprise of -50%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Heron Therapeutics, which ...